NeurAxis's robust sales growth and disciplined cost management have set the stage for achieving cash flow breakeven in 2026. Notably, recent investments from life science-focused funds have bolstered ...

NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing ...

NeurAxis (NRXS) announced that CEO Brian Carrico has published a letter to shareholders. “We are thrilled to connect with you as we celebrate ...

Eko Health, a leader in applying artificial intelligence (AI) for the early detection of heart and lung diseases, today ...

Q2 2025 Earnings Call Transcript January 8, 2025 AngioDynamics, Inc. beats earnings expectations. Reported EPS is $-0.04, ...

CEO Jensen Huang told Yahoo Finance that Nvidia is racing to get its next-gen Blackwell chips 'into every data center in the world.' ...

Bolt Acquisition Deal Drives BSX Stock Close to 52-Week High Boston Scientific stock is currently trading close to its 52-week high. In the past four trading sessions, the stock has consistently ...

The report also indicates that while PAMA has cut spending on routine tests, overall lab spending has risen as genetic testing continues to grow.

A discussion with Campbell Rogers, MD, regarding advances in AI technology for prevention and management of coronary artery disease.

AngioDynamics' NanoKnife FDA clearance boosts its potential in cancer treatment. Read why ANGO stock is a buy with its growth ...

Outpatient spine procedures have seen explosive growth over the last 10 years — a pattern that could continue as technology rapidly advances in the industry.